As 2024 comes to a close and the Health Care Committee looks back at an eventful year (for the Committee and the health care and life sciences restructuring space as a whole), activity remains strong across the health care and life sciences restructuring industry, with health care systems, facilities and providers, pharmaceutical companies and diagnostics companies of varying sizes seeking strategic and financial transactions or expedited sales processes, often with the protection of the U.S. bankruptcy courts.